Alzamend Neuro Inc (ALZN NASDAQ) stock market data APIs
$1.16
0(0%)
as of January 17, 2025
Alzamend Neuro Inc Financial Data Overview
Price chart is built with
Anychart
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Prev. Close
1.16
Open
1.16
Volume
57 475
High
1.16
Low
1.132
52 wk Range
1.06-12.9
Market Cap
6 302 K
Shares Outstanding
5 433 K
Revenue
0
EPS
-0.4
Beta
-0.038
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alzamend Neuro Inc data using free add-ons & libraries
Get Alzamend Neuro Inc Fundamental Data
Alzamend Neuro Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -7 323 379
- Earnings Per Share: -138
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-01
- EPS/Forecast: -0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alzamend Neuro Inc News
New
Insiders Are Buying These 11 Penny Stocks
In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock ma...
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech...
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it’s not particularly likely to happen. Indeed, such an endeavor requires a penchant fo...
10 Biotech Stocks With The Biggest Upside
In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
